A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910